Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

PF-05212384

Known as: PF 05212384 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
This study investigated the antitumour effects of two dual mTOR/PI3K inhibitors, gedatolisib (WYE-129587/PKI-587/PF-05212384) and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2017
2017
BackgroundThis phase I, four-arm, open-label study (NCT01347866) evaluated the PI3K/mTOR inhibitors PF-04691502 (arms A, B) and… Expand
  • table 2
  • table 3
  • table 4
  • figure 1
  • figure 2
2016
2016
OBJECTIVE PF-04691502 and gedatolisib (PF-05212384) are potent, dual PI3K/mTOR inhibitors. This phase II study (B1271004) was… Expand
  • figure 1
  • table 2
  • table 3
  • figure 2
2016
2016
The Phosphatidyl inositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and c-Met signaling pathways are often… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
2016
2016
2566Background: Inhibition of phosphatidylinositol-3-kinase (PI3K)-mediated signaling may overcome resistance to chemotherapy or… Expand
Highly Cited
2015
Highly Cited
2015
Purpose: To evaluate safety (primary endpoint), tolerability, pharmacokinetics, pharmacodynamic profile, and preliminary activity… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
2015
2015
Purpose: Radiation remains a mainstay for the treatment of nonmetastatic head and neck squamous cell carcinoma (HNSCC), a… Expand
  • table 1
Highly Cited
2015
Highly Cited
2015
Purpose: Head and neck squamous cell carcinomas exhibit variable sensitivity to inhibitors of the PI3K/mTOR pathway, an important… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2014
2014
A novel pan ERBB inhibitor PF-00299804 (dacomitinib) is currently in phase II clinical trials in glioblastoma multiforme (GBM… Expand
Highly Cited
2014
Highly Cited
2014
Background:Cetuximab is the only targeted agent approved for the treatment of head and neck squamous cell carcinomas (HNSCC), but… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5